These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

272 related items for PubMed ID: 9216839

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Synthesis and evaluation of polycyclic pyrazolo[3,4-d]pyrimidines as PDE1 and PDE5 cGMP phosphodiesterase inhibitors.
    Xia Y, Chackalamannil S, Czarniecki M, Tsai H, Vaccaro H, Cleven R, Cook J, Fawzi A, Watkins R, Zhang H.
    J Med Chem; 1997 Dec 19; 40(26):4372-7. PubMed ID: 9435906
    [Abstract] [Full Text] [Related]

  • 3. Inhibitory effects of flavonoids on phosphodiesterase isozymes from guinea pig and their structure-activity relationships.
    Ko WC, Shih CM, Lai YH, Chen JH, Huang HL.
    Biochem Pharmacol; 2004 Nov 15; 68(10):2087-94. PubMed ID: 15476679
    [Abstract] [Full Text] [Related]

  • 4. The discovery of tadalafil: a novel and highly selective PDE5 inhibitor. 2: 2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione analogues.
    Daugan A, Grondin P, Ruault C, Le Monnier de Gouville AC, Coste H, Linget JM, Kirilovsky J, Hyafil F, Labaudinière R.
    J Med Chem; 2003 Oct 09; 46(21):4533-42. PubMed ID: 14521415
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Experimental studies on guanosine 3',5'-cyclic monophosphate levels and airway responsiveness of the novel phosphodiesterase type 5 inhibitor SR 265579 in guinea-pigs.
    Kapui Z, Schaeffer P, Mikus EG, Boronkay E, Gyürky J, Herbert JM, Pascal M.
    Arzneimittelforschung; 1999 Aug 09; 49(8):685-93. PubMed ID: 10483515
    [Abstract] [Full Text] [Related]

  • 7. Phosphodiesterase inhibitors in airways disease.
    Fan Chung K.
    Eur J Pharmacol; 2006 Mar 08; 533(1-3):110-7. PubMed ID: 16458289
    [Abstract] [Full Text] [Related]

  • 8. Optimization of purine based PDE1/PDE5 inhibitors to a potent and selective PDE5 inhibitor for the treatment of male ED.
    Boyle CD, Xu R, Asberom T, Chackalamannil S, Clader JW, Greenlee WJ, Guzik H, Hu Y, Hu Z, Lankin CM, Pissarnitski DA, Stamford AW, Wang Y, Skell J, Kurowski S, Vemulapalli S, Palamanda J, Chintala M, Wu P, Myers J, Wang P.
    Bioorg Med Chem Lett; 2005 May 02; 15(9):2365-9. PubMed ID: 15837326
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Time-dependent involvement of cAMP and cGMP in consolidation of object memory: studies using selective phosphodiesterase type 2, 4 and 5 inhibitors.
    Rutten K, Prickaerts J, Hendrix M, van der Staay FJ, Sik A, Blokland A.
    Eur J Pharmacol; 2007 Mar 08; 558(1-3):107-12. PubMed ID: 17207788
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. New pyrazolo[1',5':1,6]pyrimido[4,5-d]pyridazin-4(3H)-ones as potent and selective PDE5 inhibitors.
    Feixas J, Giovannoni MP, Vergelli C, Gavaldà A, Cesari N, Graziano A, Dal Piaz V.
    Bioorg Med Chem Lett; 2005 May 02; 15(9):2381-4. PubMed ID: 15837329
    [Abstract] [Full Text] [Related]

  • 13. 1-Arylnaphthalene lignan: a novel scaffold for type 5 phosphodiesterase inhibitor.
    Ukita T, Nakamura Y, Kubo A, Yamamoto Y, Takahashi M, Kotera J, Ikeo T.
    J Med Chem; 1999 Apr 08; 42(7):1293-305. PubMed ID: 10197972
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Quinolines as extremely potent and selective PDE5 inhibitors as potential agents for treatment of erectile dysfunction.
    Bi Y, Stoy P, Adam L, He B, Krupinski J, Normandin D, Pongrac R, Seliger L, Watson A, Macor JE.
    Bioorg Med Chem Lett; 2004 Mar 22; 14(6):1577-80. PubMed ID: 15006407
    [Abstract] [Full Text] [Related]

  • 16. Implications of PDE4 structure on inhibitor selectivity across PDE families.
    Ke H.
    Int J Impot Res; 2004 Jun 22; 16 Suppl 1():S24-7. PubMed ID: 15224132
    [Abstract] [Full Text] [Related]

  • 17. Differential inhibition of multiple cAMP phosphodiesterase isozymes by isoflavones and tyrphostins.
    Nichols MR, Morimoto BH.
    Mol Pharmacol; 2000 Apr 22; 57(4):738-45. PubMed ID: 10727520
    [Abstract] [Full Text] [Related]

  • 18. Selective blockade of phosphodiesterase types 2, 5 and 9 results in cyclic 3'5' guanosine monophosphate accumulation in retinal pigment epithelium cells.
    Diederen RM, La Heij EC, Markerink-van Ittersum M, Kijlstra A, Hendrikse F, de Vente J.
    Br J Ophthalmol; 2007 Mar 22; 91(3):379-84. PubMed ID: 16943225
    [Abstract] [Full Text] [Related]

  • 19. Synthesis, structure-activity relationships, and pharmacological profile of 9-amino-4-oxo-1-phenyl-3,4,6,7-tetrahydro[1,4]diazepino[6, 7,1-hi]indoles: discovery of potent, selective phosphodiesterase type 4 inhibitors.
    Burnouf C, Auclair E, Avenel N, Bertin B, Bigot C, Calvet A, Chan K, Durand C, Fasquelle V, Féru F, Gilbertsen R, Jacobelli H, Kebsi A, Lallier E, Maignel J, Martin B, Milano S, Ouagued M, Pascal Y, Pruniaux MP, Puaud J, Rocher MN, Terrasse C, Wrigglesworth R, Doherty AM.
    J Med Chem; 2000 Dec 14; 43(25):4850-67. PubMed ID: 11123995
    [Abstract] [Full Text] [Related]

  • 20. Cardiovascular implications in the use of PDE5 inhibitor therapy.
    Maurice DH.
    Int J Impot Res; 2004 Jun 14; 16 Suppl 1():S20-3. PubMed ID: 15224131
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.